Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 1
1(33.3%)
3Total
N/A(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03670017Not ApplicableTerminated

Glucose Time-In-Range Development Evaluation

Role: collaborator

NCT02211300Not ApplicableUnknown

MANAGE Automated Glucose Monitoring

Role: lead

NCT01720381Completed

OptiScanner Versus Standard Blood Glucose Monitoring

Role: lead

NCT01135771Phase 1Completed

Performance Study Using the OptiScanner on Healthy Diabetics

Role: collaborator

All 4 trials loaded